Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 8/20 | 0.68 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.68 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.68 |
| ▸ | TSHR | P16473 | 1/20 | 0.68 |
| ▸ | HTR2A | P28223 | 1/20 | 0.68 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.68 |
| ▸ | FBP1 | P09467 | 8/20 | 0.54 |
| ▸ | PPARG | P37231 | 5/20 | 0.50 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.42 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3484747 | 0.96 | PPARA (0.62) | PPARAABCB11CYP1A2CYP3A4TSHR | |
| SCHEMBL3483913 | 0.96 | PPARA (0.62) | PPARAABCB11CYP1A2CYP3A4TSHR | |
| SCHEMBL3484192 | 0.93 | PPARA (0.59) | PPARAABCB11CYP1A2CYP3A4TSHR | |
| SCHEMBL1349983 | 0.88 | PPARA (0.64) | PPARAABCB11CYP1A2CYP3A4TSHR | |
| SCHEMBL13763797 | 0.87 | PPARA (0.71) | PPARAABCB11CYP1A2CYP3A4TSHR | |
| SCHEMBL3291229 | 0.86 | PPARA (0.69) | PPARAABCB11CYP1A2CYP3A4TSHR | |
| SCHEMBL1549122 | 0.84 | PPARA (0.68) | PPARAABCB11CYP1A2CYP3A4TSHR | |
| SCHEMBL14122275 | 0.84 | PPARA (0.50) | PPARAABCB11CYP1A2CYP3A4TSHR | |
| SCHEMBL1154731 | 0.84 | PPARA (0.71) | PPARAABCB11CYP1A2CYP3A4TSHR | |
| SCHEMBL3483751 | 0.84 | FBP1 (0.52) | PPARAABCB11CYP1A2CYP3A4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7553867-B2 | Furan or thiophene derivative and medicinal use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-30 | — | — | US | disclosed |
| US-7553867-B2 | Furan or thiophene derivative and medicinal use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-30 | — | — | US | disclosed |
| US-7507832-B2 | Triazole PPAR modulators | ELI LILLY AND COMPANY (US) | 2009-03-24 | — | — | US | disclosed |
| US-7507832-B2 | Triazole PPAR modulators | ELI LILLY AND COMPANY (US) | 2009-03-24 | — | — | US | disclosed |
| US-20090062358-A1 | PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONISTS | CANO IVAN COLLADO | 2009-03-05 | — | — | US | disclosed |
| EP-1513796-B1 | PHENYLOXYALKANOIC ACID DERIVATIVES AS HPPAR ACTIVATORS | SMITHKLINE BEECHAM CORP (US) | 2008-02-13 | — | — | EP | disclosed |
| EP-1335908-B1 | PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONISTS | LILLY CO ELI (US) | 2008-02-13 | — | — | EP | disclosed |
| US-7304062-B2 | Peroxisome proliferator activated receptor alpha agonists | ELI LILLY AND COMPANY (US) | 2007-12-04 | — | — | US | disclosed |
| US-7241793-B2 | Phenyloxyalkanonic acid derivatives as hPPAR activators | SMITHKLINE BEECHAM CORPORATION (US) | 2007-07-10 | — | — | US | disclosed |
| US-7241793-B2 | Phenyloxyalkanonic acid derivatives as hPPAR activators | SMITHKLINE BEECHAM CORPORATION (US) | 2007-07-10 | — | — | US | disclosed |
| WO-2006004903-A2 | 1,2-BIS-(SUBSTITUTED-PHENYL)-2-PROPEN-1-ONES AND PHARMACEUTICAL COMPOSITIONS THEREOF | ATHEROGENICS, INC. (US) | 2006-01-12 | — | — | WO | disclosed |
| US-20050222424-A1 | Phenyloxyalkanonic acid derivatives as hppar activators | SMITHKLINE BEECHAM CORPORATION | 2005-10-06 | — | — | US | disclosed |
| EP-1535915-A1 | FURAN OR THIOPHENE DERIVATIVE AND MEDICINAL USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2005-06-01 | — | — | EP | disclosed |
| EP-1513796-A2 | PHENYLOXYALKANOIC ACID DERIVATIVES AS HPPAR ACTIVATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-03-16 | — | — | EP | disclosed |
| US-20040102500-A1 | Peroxisome proliferator activated receptor alpha agonists | CANO IVAN COLLADO (ES) | 2004-05-27 | — | — | US | disclosed |
| WO-2004000785-A2 | PHENYLOXYALKANONIC ACID DERIVATIVES AS HPPAR ACTIVATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-12-31 | — | — | WO | disclosed |
| EP-1335908-A2 | PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONISTS | ELI LILLY AND COMPANY (US) | 2003-08-20 | — | — | EP | disclosed |
| WO-2002038553-A2 | TRIAZOLE DERIVATIVES AND THEIR USE AS PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONISTS | ELI LILLY AND COMPANY (US) | 2002-05-16 | — | — | WO | disclosed |
| US-4461905-A | THROMBOXANE SYNTHETASE INHIBITOR INTERMEDIATE | ONO PHARMACEUTICAL CO., LTD. (JP) | 1984-07-24 | — | — | US | disclosed |
| US-4214094-A | ANTILIPEMIC AGENTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1980-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102500-A1 | Peroxisome proliferator activated receptor alpha agonists | PPARG, PPARA, PPARD | PPARA 2/4885ABCB11 939/4885CYP1A2 430/4885 |
| US-20050222424-A1 | Phenyloxyalkanonic acid derivatives as hppar activators | CEL, HPN, LIPA | PPARA 54/4885ABCB11 18/4885CYP1A2 688/4885 |
| US-20090062358-A1 | PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONISTS | PPARG, PPARA, PPARD | PPARA 2/4885ABCB11 1139/4885CYP1A2 452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.